Navigation Links
WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
Date:4/10/2013

SHANGHAI, April 10, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2013 after the New York Stock Exchange closes on Monday, May 13, 2013 (which will be Tuesday morning, May 14, 2013 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, May 14, 2013, to discuss the first-quarter 2013 financial results and recent business activities. The conference call may be accessed by calling: United States:

1-866-519-4004 China (Landline):

800-819-0121 China (Mobile):

400-620-8038Hong Kong:

800-930-346United Kingdom:

0-808-234-6646International:

+65-6723-9381 Conference ID: 35582613A telephone replay will be available two hours after the call's completion at:

United States:

1-855-452-5696 China (Landline):

800-870-0205China (Mobile):

400-120-0932Hong Kong:

800-963-117United Kingdom:

0-808-234-0072International:

+61-2-8199-0299 Conference ID:

35582613A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
2. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
3. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
4. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
5. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
6. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
7. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
8. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
9. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
10. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
11. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and ... primary and secondary endpoint data for lasmiditan, an investigational, ... which demonstrated statistically significant improvements compared to placebo in ... highlighted today at the 18th Congress of the International ... "The data presented today demonstrate lasmiditan,s potential ...
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete Coatings announced that ... rely on safety and cleanliness. This unique flooring system uses silver ion technology ... for centuries for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, silver ...
(Date:9/20/2017)... ... September 20, 2017 , ... Renal Support Network’s annual essay ... kidney disease. The theme “Describe a positive decision that you have made about ... meet only one qualification— to have been diagnosed with chronic kidney disease. This ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... medical device compliance and commercialization, has just released a new white paper ... is more adamant than ever about medical device, pharmaceutical, and combination product ...
(Date:9/20/2017)... ... September 20, 2017 , ... Demand generation pioneer True ... edition of MarTech: The Marketing Tech Conference October 2–4, at the Hynes Convention ... speakers — representing such thought-leading companies as JP Morgan Chase, GE Digital, ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part ... company recently unveiled a redesigned website. The new site – still located at ... owners, architects, contractors and other industry users that Garland serves. , After an ...
Breaking Medicine News(10 mins):